OVERVIEW
This domain avexim.eu currently has an average traffic classification of zero (the lower the more users). We have scanned two pages within the domain avexim.eu and found zero websites interfacing with avexim.eu.
Pages Crawled
2AVEXIM.EU RANKINGS
This domain avexim.eu has seen alternating quantities of traffic all over the year.
Date Range
1 week
1 month
3 months
This Year
Last Year
All time
Date Range
All time
This Year
Last Year
Date Range
All time
This Year
Last Year
Last Month
LINKS TO WEB SITE
WHAT DOES AVEXIM.EU LOOK LIKE?
AVEXIM.EU HOST
I discovered that a lone root page on avexim.eu took nine hundred and fifty-three milliseconds to load. We could not detect a SSL certificate, so therefore our parsers consider avexim.eu not secure.
Load time
0.953 secs
SSL
NOT SECURE
Internet Protocol
195.88.51.10
BROWSER ICON
SERVER OS
I identified that this website is employing the LiteSpeed os.PAGE TITLE
PHU AVEXIM SP. z o.o. Handel detaliczny i hutrowy. Branża spożywcza.DESCRIPTION
Top Market Lublin - sieć polskich hipermarketów, PHU AVEXIM, handel detaliczny i hurtowy.CONTENT
This domain avexim.eu has the following in the web site, "Top Market Turka, Bukowa 2." We analyzed that the website also stated " Minuta 8, Głuska 133." It also stated " Minuta 8, Konwaliowa 7. Top Market 1-go Maja 34. Top Market Mełgiew, Kościelna 7. Top Market Nowy Świat 38 F. Top Market Świdnik, Niepodległości 24. Top Martet, Łęczna, Podzamcze 254. Witamy na stronach firmy AVEXIM Sp. Ul Raabego 3, Lublin. Pon-pt 6-20, sob 6-16,." The header had Sklepy Tom Market as the highest ranking search term. It was followed by obsługa gastronomiczna szkół i przedszkoli. Handel detaliczny i hurtowy w Lublinie which isn't as ranked as highly as Sklepy Tom Market.SEEK OTHER DOMAINS
AveXis A Clinical-stage Gene Therapy Biotech Company
AveXis is a clinical-stage gene therapy company relentlessly focused on bringing gene therapy out of the lab and into the clinical setting for patients and families devastated by rare and orphan neurological genetic diseases. Our lead gene therapy candidate, AVXS-101, is currently being evaluated in a pivotal clinical trial for the treatment of SMA Type 1, and in a Phase 1 clinical trial for the treatment of SMA Type 2.